Lupin traded at 624.00 this Wednesday June 29th, decreasing 9.45 or 1.49 percent since the previous trading session. Looking back, over the last four weeks, Lupin lost 1.81 percent. Over the last 12 months, its price fell by 45.70 percent. Looking ahead, we forecast Lupin to be priced at 613.74 by the end of this quarter and at 562.05 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
624.00
Daily Change
-1.49%
Yearly
-45.70%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Bharat Petroleum 319.30 0.70 0.22% -31.79%
Cipla 946.45 1.35 0.14% -2.62%
Dr.Reddys Laboratories 4,365.00 -9.60 -0.22% -19.51%
Reliance Infra 2,593.80 66.10 2.62% 22.89%
Sun Pharmaceuticals 839.05 10.45 1.26% 24.22%
UPL 643.55 -12.45 -1.90% -18.83%

Indexes Price Day Year
NIFTY 50 15799 -51.10 -0.32% 0.49%

Lupin
Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.